Gene Therapy for Mucopolysaccharidosis - A Pipeline Analysis Report

ムコ多糖症の遺伝子治療-パイプライン分析レポート

◆タイトル:Gene Therapy for Mucopolysaccharidosis - A Pipeline Analysis Report
◆商品コード:IRTNTR20377
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年2月27日
◆ページ数:83
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"ムコ多糖症の遺伝子治療-パイプライン分析レポート"について調査・分析し、エグゼクティブサマリー、市場規模及び予測等の情報をお届けいたします。

This pipeline analysis report provides detailed insights into the clinical trials landscape of the gene therapy for mucopolysaccharidosis including molecules at pre-clinical and various other development stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations including route of administrationKey questions answered in the report include
• What are the gene therapy molecules in the various development stages for mucopolysaccharidosis?
• What are the companies that are currently involved in the development of gene therapy molecules for mucopolysaccharidosis?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule.

【資料の目次】

Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: GENE THERAPY FOR MUCOPOLYSACCHARIDOSES: AN INSIGHT
• Introduction
• MAJOR REGULATORY AUTHORITIES
• US
• Europe
• Japan
• Australia
• China

PART 05: PIPELINE LANDSCAPE

PART 06: COMPARATIVE ANALYSIS
• Mid-stage molecules (Phase I/II), 2017
• Early-stage molecules (pre-IND and IND), 2017
• Pre-clinical stage molecules, 2017
• Suspended molecule, 2017

PART 07: INDICATION ANALYSIS

PART 08: THERAPEUTIC ASSESSMENT BY ROA

PART 09: KEY COMPANIES
• Active companies: Category and parameters
• APPENDIX
• List of abbreviations


Exhibit 01: Drug approval process by US FDA
Exhibit 02: Pipeline molecules (active) by vendors
Exhibit 03: Pipeline landscape
Exhibit 04: Pipeline molecules in different developmental stages 2017
Exhibit 05: Percentage of pipeline molecules in different developmental stages 2017
Exhibit 06: Overview: ABO-101
Exhibit 07: Clinical trials description of ABO-101
Exhibit 08: Overview: ABO-102
Exhibit 09: Clinical trials description of AB0-102
Exhibit 10: Overview: SAF-301
Exhibit 11: Clinical trials description of SAF-301
Exhibit 12: Overview: SAF302
Exhibit 13: Overview: SB-913
Exhibit 14: Clinical trials description of SB-913
Exhibit 15: Overview: SB-318
Exhibit 16: Clinical trials description of SB-318
Exhibit 17: Overview: EGT-101
Exhibit 18: Clinical trials description of EGT-101
Exhibit 19: Overview: Autologous ex-vivo lentiviral gene therapy
Exhibit 20: Overview: RGX-111
Exhibit 21: Overview: RGX-121
Exhibit 22: Overview: EGT-201
Exhibit 23: Overview: EGT-301
Exhibit 24: Overview: Gene therapy for mucopolysaccharidosis I (Hurler’s syndrome)
Exhibit 25: Overview: SOBI003
Exhibit 26: Suspended molecule, 2017
Exhibit 27: Analysis by type of indication
Exhibit 28: Assessment by RoA
Exhibit 29: Assessment of gene therapy for mucopolysaccharidosis by stage and RoA
Exhibit 30: Active companies: Category and parameters 2017
Exhibit 31: Segmentation of companies 2017
Exhibit 32: Overview: Abeona Therapeutics
Exhibit 33: Overview: ESTEVE
Exhibit 34: Overview: Immusoft
Exhibit 35: Overview: Lysogene
Exhibit 36: Overview: Orchard Therapeutics
Exhibit 37: Overview: REGENXBIO
Exhibit 38: Overview: Sangamo Therapeutics
Exhibit 39: Overview: Swedish Orphan Biovitrum
Exhibit 40: Overview: uniQure



★調査レポート[ムコ多糖症の遺伝子治療-パイプライン分析レポート] (Gene Therapy for Mucopolysaccharidosis - A Pipeline Analysis Report / IRTNTR20377)販売に関する免責事項
[ムコ多糖症の遺伝子治療-パイプライン分析レポート] (Gene Therapy for Mucopolysaccharidosis - A Pipeline Analysis Report / IRTNTR20377)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆